SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Integrated BioPharma, Inc. (INBP) 当前追踪市盈率 (P/E) 为 10.8. 追踪盈利收益率为 9.23%. PEG 0.02 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
- VALUE (100/100, 通过) — 市盈率低于市场平均水平 (10.8); PEG ≤ 1.0 — Peter Lynch 低估标准 (0.02); 盈利收益率超过债券收益率 (9.23%).
- PEG 比率 0.02 — 低于1.0表明股票相对于其盈利增长率被低估（Peter Lynch 标准）。
- 追踪盈利收益率 9.23% — 超过典型债券收益率（约4.3%），使股票相对固定收益更具吸引力。
SharesGrow 综合评分： 62/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — INBP
估值倍数
P/E (TTM)10.8
前瞻 P/EN/A
PEG 比率0.02
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.16
EV/EBITDA0.0
每股数据
EPS (TTM)$0.03
每股账面价值$0.00
每股营收$1.74
每股自由现金流$0.00
收益率与内在价值
盈利收益率9.23%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$0.05 |
$42.21M |
$958K |
2.3% |
| 2017 |
$0.10 |
$46.95M |
$2.35M |
5% |
| 2018 |
$0.02 |
$43.71M |
$679K |
1.6% |
| 2019 |
$0.06 |
$49.98M |
$1.69M |
3.4% |
| 2020 |
$0.13 |
$52.77M |
$4.11M |
7.8% |
| 2021 |
$0.25 |
$63.56M |
$8.01M |
12.6% |
| 2022 |
$0.12 |
$56.25M |
$3.84M |
6.8% |
| 2023 |
$0.00 |
$50.67M |
$-34K |
-0.1% |
| 2024 |
$0.00 |
$50.32M |
$112K |
0.2% |
| 2025 |
$0.03 |
$54.35M |
$808K |
1.5% |
